Bridgeway Capital Management LLC Purchases 50,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Bridgeway Capital Management LLC grew its position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) by 333.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,000 shares of the company's stock after acquiring an additional 50,000 shares during the period. Bridgeway Capital Management LLC owned about 0.21% of TriSalus Life Sciences worth $326,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of TLSI. Renaissance Technologies LLC purchased a new stake in shares of TriSalus Life Sciences in the 4th quarter worth about $67,000. Northern Trust Corp lifted its holdings in TriSalus Life Sciences by 22.7% in the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after buying an additional 5,936 shares during the period. Bank of America Corp DE boosted its position in TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock valued at $894,000 after acquiring an additional 178,298 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock worth $1,023,000 after acquiring an additional 3,710 shares during the period. 2.58% of the stock is owned by institutional investors.

Analyst Ratings Changes

TLSI has been the topic of several research reports. Canaccord Genuity Group restated a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Roth Mkm reissued a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Finally, Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $10.93.

TriSalus Life Sciences Trading Up 1.8%

NASDAQ:TLSI opened at $5.11 on Tuesday. The company has a 50 day simple moving average of $5.41 and a two-hundred day simple moving average of $4.98. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $10.24. The company has a market cap of $164.91 million, a PE ratio of -2.05 and a beta of 0.50.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The firm had revenue of $8.26 million for the quarter, compared to analysts' expectations of $8.12 million. Research analysts forecast that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.